8-K: Immunocore Announces $300 Million Convertible Notes Offering and Preliminary 2023 Revenue

Immunocore reports preliminary 2023 revenue of $235 million and announces a $300 million convertible notes offering to accelerate clinical pipeline and commercial expansion.

Summary

• Immunocore expects to report approximately $66 million in net product revenue from KIMMTRAK sales for the fourth quarter of 2023.
• The company estimates full-year 2023 net product revenue to be around $235 million.
• Sales growth in Q4 2023 was primarily driven by continued commercial progress in the United States.
• Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to increase compared to the third quarter of 2023.
• These increases do not include unrealized foreign exchange losses.
• The company's preliminary unaudited cash and cash equivalents at December 31, 2023, were approximately $443 million.
• Immunocore is proposing a $300 million convertible senior notes offering due in 2030.
• The company also plans to grant the initial purchasers an option to buy an additional $45 million in notes.
• The net proceeds from the offering will be used to accelerate the clinical pipeline, for commercial expansion, and to repay outstanding loans.
• Any remaining proceeds will be used for working capital and general corporate purposes.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting strong revenue growth and a significant capital raise to fund future growth. However, there are risks associated with clinical trials and the capital raise, which temper the overall sentiment.

Positives

• KIMMTRAK sales show strong growth, particularly in the United States.
• The company has a substantial cash position of approximately $443 million.
• The convertible notes offering will provide significant capital to accelerate clinical development and commercial expansion.
• Immunocore has a diverse pipeline of clinical programs across oncology, infectious diseases, and autoimmune diseases.
• The company is progressing multiple clinical trials and expects to report data throughout 2024.
• The company is expanding the use of KIMMTRAK into new indications such as cutaneous melanoma and adjuvant therapy for uveal melanoma.

Negatives

• R&D and SG&A expenses are expected to increase compared to the previous quarter.
• The preliminary financial results are unaudited and subject to change.
• The company is undertaking a significant capital raise which may dilute existing shareholders.
• The company is transitioning from IFRS to U.S. GAAP accounting standards.

Risks

• The preliminary financial results are subject to change and may differ materially from the audited results.
• The convertible notes offering is subject to market conditions and may not be completed on the anticipated terms.
• Clinical trial results may not be positive, and product candidates may not receive regulatory approval.
• The company faces competition in the biotechnology industry.
• The company's financial performance is dependent on the success of its product candidates.
• The company is subject to risks related to foreign exchange fluctuations.

Future Outlook

Immunocore intends to use the proceeds from the convertible notes offering to accelerate its clinical pipeline and commercial expansion. The company expects to report data from multiple clinical trials throughout 2024 and is advancing several product candidates towards regulatory submissions.

Management Comments

• The company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to accelerate its clinical pipeline and for ongoing commercial expansion.
• The company intends to repay in full loans outstanding under its loan agreement with investment funds managed by Pharmakon Advisors, LP.
• The company intends to use any remaining proceeds for other working capital and general corporate purposes.

Industry Context

Immunocore is operating in the competitive biotechnology sector, focusing on novel TCR bispecific immunotherapies. The company's focus on solid tumors and infectious diseases aligns with current industry trends in cancer and infectious disease therapeutics. The company's ImmTAX platform is a novel approach to cancer treatment and is competing with other bispecific and immunotherapy approaches.

Comparison to Industry Standards

• Immunocore's KIMMTRAK is the first approved therapy for uveal melanoma in four decades, setting a new standard in this niche market.
• The company's clinical pipeline, including IMC-F106C, is competing with other bispecific and checkpoint inhibitor combinations in solid tumors, such as those being developed by companies like Regeneron and Bristol Myers Squibb.
• The company's focus on TCR-based therapies is a differentiated approach compared to more common antibody-based immunotherapies.
• The company's cash position of $443 million is relatively strong compared to other biotech companies of similar size, but the capital raise is significant.
• The company's revenue of $235 million for 2023 is a good result for a commercial-stage biotech company, but it is still early in the commercialization phase.

Stakeholder Impact

• Shareholders may experience dilution due to the convertible notes offering.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the development of new therapies.
• Creditors will be repaid through the proceeds of the offering.
• Suppliers may see increased business due to the company's expansion.

Next Steps

• Complete the convertible notes offering.
• Continue commercialization of KIMMTRAK.
• Advance clinical trials for multiple product candidates.
• Submit IND or CTA applications for IMC-P115C and IMC-T119C.
• Report data from ongoing clinical trials throughout 2024.

Key Dates

Keywords

Immunocore, KIMMTRAK, Tebentafusp, Convertible Notes, Clinical Trials, ImmTAX, ImmTAV, ImmTAAI, Oncology, Uveal Melanoma, Biotechnology, PRAME, PIWIL1, HIV, Hepatitis B, Autoimmune, Type 1 Diabetes